Blog

Slide background
Slide background
Slide background
Slide background
Slide background
Slide background
Slide background
Slide background
Slide background

InnovoSep

InnovoSep is developing new therapies for sepsis based on Cilengitide. Cilengitide has been shown to prevent binding to the endothelium for pathogens such as S. aureus and E. coli thereby inhibiting the main mechanism by which endothelial cell dysfunction in sepsis leads to septic shock and organ failure. This novel, non-antibiotic approach represents a promising new treatment pathway for patients with sepsis.

www.rcsi.ie